Literature DB >> 10349994

The expression of hamartin, the product of the TSC1 gene, in normal human tissues and in TSC1- and TSC2-linked angiomyolipomas.

T L Plank1, H Logginidou, A Klein-Szanto, E P Henske.   

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by seizures, mental retardation, and hamartomatous tumors in multiple organs, including subependymal giant cell astrocytomas, cardiac rhabdomyomas, and renal angiomyolipomas. Mutations in two genes are associated with TSC: TSC1, which was cloned in 1997, and TSC2, which was cloned in 1993. We report here the expression of hamartin, the product of the TSC1 gene, in normal human tissues and in renal angiomyolipomas from TSC1- and TSC2-linked patients. By Western blot analysis, hamartin is strongly expressed in brain, kidney, and heart, all of which are frequently affected in TSC. By immunohistochemical analysis, the expression pattern of hamartin in normal human tissues was almost identical to that of tuberin, the product of the TSC2 gene. This is consistent with the recent finding that tuberin and hamartin interact and with the clinical similarity between TSC1- and TSC2-linked disease. Strong hamartin expression was seen in cortical neurons, renal tubular epithelial cells, pancreatic islet cells, bronchial epithelial cells, and pulmonary macrophages. Hamartin was also expressed in endocrine tissues, including islet cells of the pancreas, follicular cells of the thyroid, and the zona reticularis of the adrenal cortex. In eight angiomyolipomas from a TSC1-linked patient, no hamartin expression was detected, whereas tuberin, the product of the TSC2 gene, was expressed. In 19 angiomyolipomas from a TSC2-linked patient, in whose angiomyolipomas loss of tuberin expression had previously been shown, hamartin expression was present. These data suggest that tuberin and hamartin immunoreactivity can distinguish tumors with underlying TSC1 mutations from those with TSC2 mutations. This differentiation might have diagnostic implications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10349994

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  17 in total

1.  Emerging therapies and latest development in the treatment of unresectable pancreatic neuroendocrine tumors: an update for clinicians.

Authors:  Jaya Sharma; Marvin Duque; M Wasif Saif
Journal:  Therap Adv Gastroenterol       Date:  2013-11       Impact factor: 4.409

Review 2.  Tuberous sclerosis complex: a review of the management of epilepsy with emphasis on surgical aspects.

Authors:  Mary B Connolly; Glenda Hendson; Paul Steinbok
Journal:  Childs Nerv Syst       Date:  2006-06-13       Impact factor: 1.475

3.  Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions.

Authors:  Y Niida; A O Stemmer-Rachamimov; M Logrip; D Tapon; R Perez; D J Kwiatkowski; K Sims; M MacCollin; D N Louis; V Ramesh
Journal:  Am J Hum Genet       Date:  2001-07-20       Impact factor: 11.025

Review 4.  The neurobiology of the tuberous sclerosis complex.

Authors:  Leah Marcotte; Peter B Crino
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 5.  Giant cells: contradiction to two-hit model of tuber formation?

Authors:  Jaroslaw Jozwiak; Sergiusz Jozwiak
Journal:  Cell Mol Neurobiol       Date:  2005-08       Impact factor: 5.046

6.  Ubiquitin hydrolase UCH-L1 destabilizes mTOR complex 1 by antagonizing DDB1-CUL4-mediated ubiquitination of raptor.

Authors:  Sajjad Hussain; Andrew L Feldman; Chittaranjan Das; Steven C Ziesmer; Stephen M Ansell; Paul J Galardy
Journal:  Mol Cell Biol       Date:  2013-01-07       Impact factor: 4.272

7.  The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: use of telomerase to obtain stable populations of cells from benign neoplasms.

Authors:  J L Arbiser; R Yeung; S W Weiss; Z K Arbiser; M B Amin; C Cohen; D Frank; S Mahajan; G S Herron; J Yang; H Onda; H B Zhang; X Bai; E Uhlmann; A Loehr; H Northrup; P Au; I Davis; D E Fisher; D H Gutmann
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

8.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

Authors:  James C Yao; Alexandria T Phan; David Z Chang; Robert A Wolff; Kenneth Hess; Sanjay Gupta; Carmen Jacobs; Jeannette E Mares; Andrea N Landgraf; Asif Rashid; Funda Meric-Bernstam
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

9.  Report from the 13th annual Western canadian gastrointestinal cancer consensus conference; calgary, alberta; september 8-10, 2011.

Authors:  M M Vickers; J Pasieka; E Dixon; S McEwan; A McKay; D Renouf; D Schellenberg; D Ruether
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

10.  Functional tyrosine kinase inhibitor profiling: a generally applicable method points to a novel role of platelet-derived growth factor receptor-beta in tuberous sclerosis.

Authors:  Jack L Arbiser; Baskaran Govindarajan; Xianhe Bai; Hiroaki Onda; Andrius Kazlauskas; So Dug Lim; Mahul B Amin; Lena Claesson-Welsh
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.